The most well-known ICMs in cancer are the programmed cell death 1 (PD-1), with its two ligands, PD-L1 and PD-L2, and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which also has two ligands, CD80 and CD86 [2]. This evidence concerns the gene CTLA4 and cancer.